Sema4 Sees Prelim. 2022 Pro-Forma Revenues $170M-$173M, Up 37-40% YoY; Co. Also Announces Name Change To GeneDx Holdings Corp. GeneDx

1/9/23 8:49:18 AM ET

Retail: Computer Software & Peripheral Equipment

Technology

Get the next $SMFR alert in real time by email

Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care.

Get the next $SMFR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SMFR

Date	Price Target	Rating	Analyst
12/7/2022	$3.00 → $1.00	Buy → Neutral	Goldman
8/16/2022	$4.00 → $2.00	Buy → Hold	Jefferies
6/2/2022	$3.50	Buy	Goldman
11/19/2021	$12.00	Buy	Goldman Sachs
10/8/2021	$12.00	Buy	BTIG Research
9/30/2021	$13.00	Outperform	Cowen & Co.
9/24/2021	$13.00	Buy	Jefferies

More analyst ratings

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and
1/9/23 8:30:00 AM ET
$SMFR
Retail: Computer Software & Peripheral Equipment
Technology
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis® 19% pro forma1 volume growth vs. 3Q 2021 and 21% pro forma1 revenue growth vs. 3Q 2021 Sema4 to host a conference call today at 8:30 a.m. ET STAMFORD, Conn., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Sema4 Holdings Corp. (NASDAQ:SMFR) ("Sema4"), a health insights company, today announced business highlights and financial results for the third quarter ended September 30, 2022. Additionally, Sema4 announced its decision to pursue a new strategic direction focused on a $30 billion market opportunity
11/14/22 8:02:00 AM ET
$SMFR
Retail: Computer Software & Peripheral Equipment
Technology
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland, Chief Executive Officer of Sema4, and Kevin Feeley, Chief Financial Officer of Sema4, will host a conference call to discuss financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Sema4 will host a conference call on November 14, 2022, at 8:30 a.m. Eastern Time. Interested parties may access the live teleconference by dialing (866) 374-5140, followed by PIN 44463501#. A live and archived webcast
11/4/22 4:05:00 PM ET
$SMFR
Retail: Computer Software & Peripheral Equipment
Technology

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance
Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis® platforms Company's common stock will trade on the Nasdaq under new ticker "WGS" effective January 10, 2023 STAMFORD, Conn, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR) today announced it has changed its name from Sema4 Holdings Corp. to GeneDx Holdings Corp. GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic and clinical insights, is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx's industry-leading exome and
1/9/23 8:30:00 AM ET
$SMFR
Retail: Computer Software & Peripheral Equipment
Technology
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the company will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland, President and Chief Executive Officer, will deliver a formal presentation on Thursday, January 12, 2023, at 10:30 a.m. PT. A live and archived webcast of the presentation will be available on the "Events" section of the Sema4|GeneDx investor relations website at https://ir.sema4.com/. About Sema4|GeneDx Sema4|GeneDx is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming
12/30/22 8:30:00 AM ET
$SMFR
Retail: Computer Software & Peripheral Equipment
Technology
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ:SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it can lead to earlier diagnoses and more immediate potential changes in clinical management. The research evaluates the incidence of mitochondrial disease caused by both nuclear DNA (nDNA) and mtDNA in 966 infants in the NICU who received both rapid exome sequencing and mtDNA sequencing and deletion testing concurrently. Mitochondrial diseases are chronic, genetic disorders that occur when mitochondria fai
12/5/22 8:00:00 AM ET
$SMFR
Retail: Computer Software & Peripheral Equipment
Technology

Sema4 Sees Prelim. 2022 Pro-Forma Revenues $170M-$173M, Up 37-40% YoY; Co. Also Announces Name Change To GeneDx Holdings Corp. GeneDx

Chat with this insight

Recent Analyst Ratings for $SMFR

$SMFR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Ryan Jason bought $161,368 worth of shares (114,742 units at $1.41) (SEC Form 4)

Pfenniger Richard C Jr bought $14,889 worth of shares (10,000 units at $1.49), increasing direct ownership by 92% to 20,918 units (SEC Form 4)

$SMFR SEC Filings

$SMFR Financials

Live finance-specific insights

Sema4 Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 144 filed by Sema4 Holdings Corp.

SEC Form 10-Q filed by Sema4 Holdings Corp.

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

$SMFR Leadership Updates

Live Leadership Updates

Sema4 Appoints Healthcare and Diagnostics Industry Veteran Kevin Feeley as Chief Financial Officer

Sema4 Announces Chief Financial Officer Transition Plan

$SMFR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$SMFR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$SMFR Press Releases

Fastest customizable press release news feed in the world

$SMFR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Saad Kareem sold $625 worth of shares (193 units at $3.24) and converted options into 546 shares, increasing direct ownership by 1% to 24,467 units (SEC Form 4)

Ryan Jason gifted 73,614 shares, closing all direct ownership in the company (SEC Form 4)

Saad Kareem sold $271 worth of shares (105 units at $2.58), decreasing direct ownership by 0.43% to 24,114 units (SEC Form 4)

Sema4 Holdings Corp downgraded by Goldman with a new price target

Sema4 Holdings Corp downgraded by Jefferies with a new price target

Goldman resumed coverage on Sema4 Holdings Corp with a new price target

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

SEC Form SC 13G filed by Sema4 Holdings Corp.

SEC Form SC 13D/A filed by Sema4 Holdings Corp. (Amendment)

SEC Form SC 13G/A filed by Sema4 Holdings Corp. (Amendment)

$SMFR Market Insights

Live Market Insights

Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Sema4 shares are trading higher after the company announced a name change to GeneDx and issued FY22 and FY23 guidance.

Sema4 Sees Prelim. 2022 Pro-Forma Revenues $170M-$173M, Up 37-40% YoY; Co. Also Announces Name Change To GeneDx Holdings Corp. GeneDx

Recent Analyst Ratings for
$SMFR

$SMFR
Insider Purchases

$SMFR
SEC Filings

$SMFR
Financials

$SMFR
Leadership Updates

$SMFR
Insider Trading

$SMFR
Analyst Ratings

$SMFR
Press Releases

$SMFR
Large Ownership Changes

$SMFR
Market Insights